• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

    16.83 +0.28 (+1.69%)
    Streaming Delayed Price Updated: 10:26 AM EST, Feb 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Dyne Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Proposed Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Present at Upcoming Investor Conferences
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Appoints Brian Posner to its Board of Directors
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Present at Upcoming Investor Conferences
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.